Cyberonics suffers depression trial setback
This article was originally published in Clinica
Executive Summary
Cyberonics saw its shares plunge 56% last Tuesday after reporting that a pivotal trial of its vagus nerve stimulation (VNS) therapy for depression failed to show a significant difference between the treated and placebo patients. The company said that an application to market the treatment in the US as a treatment for the condition could be delayed by two to three years.